|
Stephen Spagnol, PhD
Director, Enabling Technologies
Merck
|
Stephen Spagnol is a Director of Business Development & Licensing, Enabling Technologies at Merck. He leads Search & Evaluation efforts related to mRNA/RNA, Drug Delivery & Formulation, Vaccines & Biologics Bioprocess, Cell & Gene Therapy and Gene Editing. Prior to returning to Merck, Stephen was an Associate Director at Johnson & Johnson where he led efforts for novel new modality therapeutics. He led Phase III and late-stage development for AAV gene therapy programs and development for oncolytic viruses and viral vaccines for oncology. He led novel platform development for gene therapy culminating in several patent applications. Stephen started his career at Merck and serving as a Scientific Supervisor and led formulation and process development efforts for RNA Therapeutics and mRNA Vaccines. He also led design and optimization of novel drug delivery technologies for RNA therapeutics and mRNA vaccines.
Stephen received a Ph.D. in Chemical Engineering from Carnegie Mellon University. Stephen completed his B.S. in Chemical Engineering from the Pennsylvania State University.
Stephen received a Ph.D. in Chemical Engineering from Carnegie Mellon University. Stephen completed his B.S. in Chemical Engineering from the Pennsylvania State University.